摘要
目的探讨免疫组化在无色素性恶性黑色素瘤诊断和鉴别诊断的应用价值。方法回顾分析３７例可疑无色素性恶性黑色素瘤的组织学特点并进行免疫组化研究。结果３７例中１６例ＨＭＢ４５、Ｓ－１００和Ｖｉｍｅｎｔｉｎ阳性，证实为恶性黑色素瘤；２１例ＨＭＢ４５阴性，阴性者中７例ｃｙｔｏｋｅｒａｔｉｎ和ＣＥＡ、ＥＭＡ阳性，诊断为癌；８例ＬＣＡ阳性，诊断为淋巴瘤，６例Ｖｉｍｅｎｔｉｎ等阳性，诊断为肉瘤。结论ＨＭＢ４５和Ｓ－１００是无色素性恶性黑色素瘤的诊断性标记物，前者更具特异性。ＨＭＢ４５联合其它相关抗体可以作为无色素性恶黑鉴别诊断指标。
Objective To study the immunohistochemical value in diagnosis and differential diagnosis of amelanotic malignant melanoma. Methods To review the histological and immunohistochemical character istic in amelanotic malignant melanoma. Results 16 of 37 cases were confirmed with amelanotic malignant melanoma by HMB45 and S100 or Vimentin.7 of 37 cases were carcinoma with HMB45, Cytokeratin+,CEA+,EMA+.8 of 27 cases were lymphoma with LCA+. Other 6 cases were sarcoma with Vimentin+. Conclusion HMB45 and S100 were diagnostic marker of malignant melanoma. HMB45 is more specific than other antibodies. HMB45 with other antibodies can be a differential diagnostic marker in amelanotic malignant melanoma.
出处
《肿瘤研究与临床》
CAS
1999年第3期173-174,共2页
Cancer Research and Clinic
关键词
黑色素瘤
免疫组化
诊断
鉴别诊断
Malignant melanomaImmunohistochemistryDifferential diagnosis
